Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

Abstract

NCT00124982.

Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?

“…In clinical trials, abatacept was effective both as monotherapy (116) and when tested in combination with MTX (117). In a study in patients who had previously received anti-TNF drugs, abatacept could induce ACR criteria responses in a significant proportion of the patients involved in the trial (118). Abatacept has been approved for the treatment of moderate-to-severe RA that has responded inadequately to other treatments.…”

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis

“…The improvements in signs and symptoms observed at 6 months were maintained through 2 years in patients originally randomized to abatacept [30]. Using an intent-totreat (ITT) analysis that included patients who discontinued (defined as non-responders) at 2 years, ACR 20, 50, and 70 response rates were 56.2%, 33.2%, and 16.1%, respectively.…”

“…At 2 years, using the post hoc as-observed analyses, nearly one-fifth of patients originally randomized to receive abatacept achieved DAS28 (CRP)-defined remission, showing that the proportion of patients in remission was maintained through the 2 years (Fig. 3b) [30]. The proportion of patients who achieved LDAS increased from 18.3% (95% CI; 13.0, 23.5) at the end of the double-blind period to 32.0% (24.6, 39.4) at 2 years with no overlap in the 95% CIs between 6 months and 2 years (Fig.…”

“…Abatacept has been shown to reduce disease activity and improve quality of life (QoL) in this difficult-to-treat patient population [29,30]. T-cell modulation with abatacept was evaluated in patients with moderate to severely active RA who had failed at least 3 months of TNF-α antagonist therapy in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trial [29].…”

“…Both groups had a high number of tender and swollen joints at baseline with a mean of 31.2±13.0 tender joints and 22.3± 10.2 swollen joints in the abatacept group, and 32.8±13.4 tender joints and 22.0±10.0 swollen joints in the placebo group. Evaluation continued during a long-term extension (LTE) period, where all continuing patients received openlabel abatacept [30]. A total of 218 (84.5%) patients originally randomized to abatacept and 99 (74.4%) patients originally randomized to placebo entered the LTE, and 222 (70.0%) of these completed a further 18 months of treatment.…”